A
Antonio Rossi
Researcher at Casa Sollievo della Sofferenza
Publications - 63
Citations - 1253
Antonio Rossi is an academic researcher from Casa Sollievo della Sofferenza. The author has contributed to research in topics: Lung cancer & Pembrolizumab. The author has an hindex of 12, co-authored 63 publications receiving 966 citations. Previous affiliations of Antonio Rossi include Yahoo! & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi,Massimo Di Maio,Paolo Chiodini,Robin M. Rudd,Hiroaki Okamoto,Dimosthenis Skarlos,Martin Früh,Wendi Qian,Tomohide Tamura,Epaminondas Samantas,Taro Shibata,Francesco Perrone,Ciro Gallo,Cesare Gridelli,Olga Martelli,Siow Ming Lee +15 more
TL;DR: A meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-line treatment of SCLC, but there are differences in the toxicity profile.
Journal ArticleDOI
Lung Cancer in the Elderly
TL;DR: Assessment of treatment for elderly lung cancer patients is hindered by the absence of prospective elderly-specific trials, but available data suggest that outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally worse.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.
Journal ArticleDOI
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
Francesco Facchinetti,Giulia Mazzaschi,Fausto Barbieri,Francesco Passiglia,Francesca Mazzoni,Rossana Berardi,Claudia Proto,Fabiana Letizia Cecere,Sara Pilotto,Vieri Scotti,Sabrina Rossi,Alessandro Del Conte,Emanuele Vita,Chiara Bennati,Andrea Ardizzoni,Giulio Cerea,Maria Rita Migliorino,Elisa Sala,Andrea Camerini,Alessandra Bearz,Elisa De Carlo,F. Zanelli,Giorgia Guaitoli,Marina Chiara Garassino,L.P. Ciccone,Giulia Sartori,Luca Toschi,Filippo Gustavo Dall'Olio,Lorenza Landi,Elio Gregory Pizzutilo,Gabriele Bartoli,Cinzia Baldessari,Silvia Novello,Emilio Bria,Diego Cortinovis,Giulio Rossi,Antonio Rossi,Giuseppe Luigi Banna,Roberta Camisa,Massimo Di Maio,Marcello Tiseo +40 more
TL;DR: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself, and the only factor independently impacting on both PFS and OS.
Journal ArticleDOI
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.
Federico Pio Fabrizio,Domenico Trombetta,Antonio Rossi,Angelo Sparaneo,Stefano Castellana,Lucia Anna Muscarella +5 more
TL;DR: The current knowledge of PD-L1 gene modifications at genetic and epigenetic levels in different tumors is summarized, thus highlighting their reported correlation with cellular processes and potential impact on patient outcomes.